ADCs increasing in clinical performance stature
The antibody-drug conjugate ifinatamab deruxtecan demonstrated “robust and durable efficacy” in patients with heavily pretreated small cell lung cancer, according to a subset analysis of the Phase I/II DS7300-A-J101 trial presented at the International Association for the Study of Lung Cancer 2023 World Conference on Lung Cancer (WCLC). The very encouraging PFS and median OS achieved in a heavily pretreated refractory SCLC population shows promising clinical and commercial prospects with this ADC approach.